Marco Gottardis

Downing Ventures (Downing Ventures) is an independent venture capital firm founded in 1986. The firm is headquartered in London.

Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark.

Zürcher Kantonalbank (Broker) (ZKB-Broker) is the brokerage business unit of Zürcher Kantonalbank, a state-owned full-service bank founded in 1870, which is headquartered in Zurich, Switzerland. They conduct all investment activities in-house including financial advisory services, research, trading, and asset management. ZKB-Broker is an active trader in securities, foreign currencies, banknotes, precious metals, commodity contracts and financial derivatives on their own account and on behalf of third-party customers. The bank provides underwriting services in domestic debt and equity markets, sales and trading of listed domestic warrants and structured derivatives, and Swiss Franc foreign exchange trading. The firm offers round-the-clock market-making in credit default swaps from Swiss issuers. Their research covers a broad international investment universe and maintains a successful equity, bonds and sustainability research capability, together with independent investment fund research.

BioMedPartners AG (BMP), is an independant venture capital firm headquartered in Basel, Switzerland. BMP originated in 2002 as Seed Capital Advisors AG. The firm manages sector-focused venture capital funds including BioMedInvest, BioMedInvest II and BioMedCredit. They specialize in the biomedical sector.

Miracor Medical SA engages in the development and manufacture of medical devices. Its product PICSO (Pressure-controlled Intermittent Coronary Sinus Occlusion) Impulse System has a driving console and associated catheters to improve outcomes for severe heart attack patients. It seeks to increase blood flow to the affected heart tissue, thereby improving the overall heart function after a heart attack. The company was founded by Werner Mohl in May, 2008 and is headquartered in Vienna, Austria.

Kizoo Technology Capital GmbH (KIZOO) is the venture capital arm of Atevia AG, itself a subsidiary of Cinetic Gesellschaft zur Entwicklung & Vertrieb von Medien. The firm was founded by Michael Greve, Matthias Hornberger, and Frank Schüler in 2006. It is headquartered in Karlsruhe, Germany.

Cell Medica Switzerland AG engages in the research, development, production, and distribution of pharmaceutical, biological, medical, and diagnostic products. It provides locally and systemically applied antibody therapeutics under the PENTRA Body platform. The company was founded by Thomas O. Hecht on September 4, 2009 and is headquartered in Schlieren, Switzerland.

APEIRON Biologics AG operates as a clinical-stage company which engages in the discovery and development of novel cancer immunotherapies. The firm develops APN311, a therapeutic antibody to treat pediatric patients with neuroblastoma; APN301, an immunocytokine consisting of a humanized antibody genetically linked to two human IL-2 molecules; and APN401, a first-in-class autologous cellular therapy. The company was founded by Josef Penninger in 2005 and is headquartered in Vienna, Austria.

BC Platforms AG provides powerful genomic data management and analysis solutions. It offers pharmaceutical, biobank, healthcare and academia products. The company was founded by Timo Kanninen in 1997 and is headquartered in Basel, Switzerland.

Qkine Ltd. provides growth factors and bioactive proteins for use in stem cell science and regenerative medicine applications. Its products include Activin A and FGF2. The firm specializes in protein purification, organoids, cytokines, and protein-engineering. The company was founded by Marko Hyvonen and Catherine Elton in 2016 and is headquartered in Cambridge, the United Kingdom.

Part of Roivant Sciences Ltd., Genevant Sciences Corp. operates as a Canadian biopharmaceutical company. The company is based in Burnaby, Canada. The CEO of the company is Bo Rode Hansen.

JFG Life Sciences Stiftung der Universität Basel engages in the promotion of innovation transfer in the field of life sciences and related areas. It also supports knowledge and technology transfer at the University of Basel. The company was founded on December 20, 2018 and is headquartered Basel, Switzerland.

Revel Pharmaceuticals, Inc. engages in the provision of therapeutic designer enzymes to degrade molecular damage that accumulates with aging. The company was founded by Aaron Cravens, David Spiegel and Jason Crawford in 2019 and is headquartered in San Francisco, CA.

Genevant Sciences, Inc. is a company based in Cambridge, MA that specializes in nucleic acid drug development and delivery. The company has developed lipid nanoparticle (LNP) technology and next-generation ligand conjugate technology for delivery of gene editing payloads, small interfering RNA (siRNA), and other oligonucleotide payloads. The company has a robust and expansive LNP patent estate and decades of experience and expertise in nucleic acid drug development. The company is committed to maximizing every opportunity to transform the future of human health by expanding their focus to extrahepatic tissues and cell types, such as the lung, stellate cells, and leukocytes. Genevant Sciences has built expertise in siRNA payload design and development and has more than 700 patents worldwide that they own or license. The company is open, collaborative, and entrepreneurial, and are always ready to connect with people interested in the pioneering work they do.

Part of Gas Sensing Solutions Ltd., Cambridge Respiratory Innovations Ltd. develops and manufactures medical devices. The private company is based in Swavesey, UK.

Vaximm AG provides active immunotherapies for patients suffering from cancer. It develops and provides vaccines for patients suffering from cancer. The firmalso provides research, development, manufacture, marketing and sale of pharmaceutical products. The company was founded in September 2008 and is headquartered in Basel, Switzerland.